Kelley Marian, Cooper Cianna, Matticoli Aileen, Greway Anthony
145 King of Prussia, Centocor, Road Radnor, PA 19087-4517, USA.
J Immunol Methods. 2005 May;300(1-2):179-91. doi: 10.1016/j.jim.2005.03.013. Epub 2005 Apr 26.
Neutralizing antibodies to erythropoietin (EPO) can cause a loss of response to recombinant human EPO (rHuEPO) and lead to rare cases of sudden, unexplained, severe anemia in chronic renal failure patients treated with rHuEPO. An assay for neutralizing anti-EPO antibodies has been validated that is based on the inhibition of proliferation of human UT-7/EPO cells, an immortalized cell line, by neutralizing antibodies in serum test samples using 3H-thymidine as a marker for proliferation. The dependence of the human cell line on EPO for growth and proliferation in a concentration-dependent manner enabled the validation of a rHuEPO standard curve for cell proliferation that can be used to determine the presence of neutralizing anti-EPO antibodies in serum samples. Proliferation of the cells increases with increasing concentrations of EPO, forming an S-shaped standard curve, which is fit with a 4-parameter logistic model, between 2.5 and 50 mU/mL rHuEPO, with a percent coefficient of variation (% CV) from 8.7% to 22.1% and a % accuracy of 103.5% to 109.5%. Anti-EPO antibodies and serum with anti-EPO antibodies neutralize UT-7/EPO proliferation by 10 mU/mL rHuEPO in a concentration- or dilution-dependent manner with < or = 25% CV. Percent neutralization is calculated by determining the amount of EPO recovered from the original 10 mU/mL added using the formula [((10-concentration recovered)/10)x100%]. Stem cell factor (SCF) stimulated cell proliferation, but not as effectively as rHuEPO. Antibodies to SCF were not able to inhibit the proliferative response induced by EPO and vice versa, confirming the specificity of the assay for antibodies to EPO. High EPO levels can impact both the radioimmunoprecipitation and neutralization assays to produce a false negative result. However, the impact can be mitigated by the large dilutions used in the neutralization assay.
促红细胞生成素(EPO)中和抗体可导致对重组人促红细胞生成素(rHuEPO)失去反应,并在接受rHuEPO治疗的慢性肾衰竭患者中引发罕见的、不明原因的严重贫血病例。一种基于抑制人UT-7/EPO细胞(一种永生化细胞系)增殖的中和抗EPO抗体检测方法已得到验证,该方法使用3H-胸腺嘧啶作为增殖标记物,通过血清检测样本中的中和抗体来抑制细胞增殖。该人类细胞系对EPO的生长和增殖呈浓度依赖性,这使得能够验证用于细胞增殖的rHuEPO标准曲线,该曲线可用于确定血清样本中中和抗EPO抗体的存在。细胞增殖随EPO浓度增加而增加,形成一条S形标准曲线,在2.5至50 mU/mL rHuEPO之间,用四参数逻辑模型拟合,变异系数百分比(% CV)为8.7%至22.1%,准确度百分比为103.5%至109.5%。抗EPO抗体和含有抗EPO抗体的血清以浓度或稀释依赖性方式,在10 mU/mL rHuEPO时中和UT-7/EPO增殖,变异系数小于或等于25%。中和百分比通过使用公式[((10 - 回收浓度)/10)×100%]确定从最初添加的10 mU/mL中回收的EPO量来计算。干细胞因子(SCF)刺激细胞增殖,但效果不如rHuEPO。抗SCF抗体不能抑制EPO诱导的增殖反应,反之亦然,这证实了该检测方法对EPO抗体的特异性。高EPO水平可影响放射免疫沉淀法和中和法,产生假阴性结果。然而,通过中和法中使用的大量稀释可减轻这种影响。